Literature DB >> 10766952

A three-dimensional model of the delta-opioid pharmacophore: comparative molecular modeling of peptide and nonpeptide ligands.

M D Shenderovich1, S Liao, X Qian, V J Hruby.   

Abstract

A comparative molecular modeling study of delta-opioid ligands was performed under the assumption that potent peptide and nonpeptide agonists may have common three-dimensional (3D) arrangement of pharmacophore groups upon binding to the delta-receptor. Low-energy conformations of the agonists 7-spiroindanyloxymorphone (SIOM) and 2-methyl-4a-alpha-(3-hydroxyphenyl)-1,2,3,4,4a,5,12, 12a-alpha-octahydro-quinolino[2,3,3-g]isoquinoline (TAN-67), and a partial agonist oxomorphindole (OMI) were determined by high-temperature molecular dynamics (MD). A good spatial overlap was found for the pharmacophore groups of SIOM, TAN-67, and OMI, including the basic nitrogen, phenol hydroxyl, and two aromatic ring. Based on this overlap we proposed a 3D pharmacophore model for nonpeptide delta-opioid agonists with a distance of 7.0 +/- 1.3 A between the two aromatic rings and of 8.2 +/- 1.0 A between the nitrogen and phenyl ring. The potent and highly delta-opioid receptor selective agonist [(2S,3R)-TMT(1)]DPDPE, which shares global backbone constraints of the 14-membered disulfide cycle and a strong preference for the trans rotamer of the TMT(1) side chain, was chosen as a peptide template of the delta-opioid pharmacophore. Extensive MD simulations at 300 K with the AMBER force field were performed for [(2S,3R)-TMT(1)]DPDPE and the less potent [(2S, 3S)-TMT(1)]DPDPE analogue. Multiple MD trajectories were collected for each peptide starting from the x-ray structures of DPDPE and [L-Ala(3)]DPDPE and from models proposed in the literature. Low-energy MD conformations were filtered by the nonpeptide pharmacophore query and then directly superimposed with SIOM, OMI, and TAN-67. Two conformers of [(2S,3R)-TMT(1)]DPDPE that showed the best overlap with the nonpeptide pharmacophore (rms deviation </= 1. 0 A for N,O atoms and centroids of two aromatic rings) were selected as possible delta-receptor binding conformations. These conformations have similar backbone structures, and trans rotamers of the TMT(1) side-chain group. They are reasonably close to the crystal structure of [L-Ala(3)]DPDPE, and differ significantly from the crystal structure of DPDPE. The conformer with a gauche(-) rotamer of Phe(4) is most consistent with structure-activity relationships of delta-opioid peptides. The proposed 3D models were used for rational design of new nonpeptide delta-receptor ligands. Copyright 2000 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10766952     DOI: 10.1002/(SICI)1097-0282(200006)53:7<565::AID-BIP4>3.0.CO;2-5

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  12 in total

1.  Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain.

Authors:  V J Hruby; R S Agnes; P Davis; S-W Ma; Y S Lee; T W Vanderah; J Lai; F Porreca
Journal:  Life Sci       Date:  2003-06-27       Impact factor: 5.037

2.  A molecular dynamics study on opioid activities of biphalin molecule.

Authors:  Jin-Yuan Hsieh; Tzen-Yuh Chiang; Jun-Liang Chen; Yun-Wen Chen; Hong-Chang Lin; Chi-Chuan Hwang
Journal:  J Mol Model       Date:  2010-12-23       Impact factor: 1.810

3.  Conformational stability and three-dimensional model of the delta-opioid pharmacophore for the extended antiparallel dimer structure of Met-enkephalin in water.

Authors:  Yng-Ching Wu; Jin-Yuan Hsieh; Hong-Chang Lin; Chi-Chuan Hwang
Journal:  J Mol Model       Date:  2006-09-14       Impact factor: 1.810

4.  Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.

Authors:  Richard S Agnes; Yeon Sun Lee; Peg Davis; Shou-Wu Ma; Hamid Badghisi; Frank Porreca; Josephine Lai; Victor J Hruby
Journal:  J Med Chem       Date:  2006-05-18       Impact factor: 7.446

5.  Novel cyclic biphalin analogue with improved antinociceptive properties.

Authors:  Adriano Mollica; Alfonso Carotenuto; Ettore Novellino; Antonio Limatola; Roberto Costante; Francesco Pinnen; Azzurra Stefanucci; Stefano Pieretti; Anna Borsodi; Reza Samavati; Ferenc Zador; Sándor Benyhe; Peg Davis; Frank Porreca; Victor J Hruby
Journal:  ACS Med Chem Lett       Date:  2014-07-14       Impact factor: 4.345

6.  Four-component pharmacophore model for endomorphins toward μ opioid receptor subtypes.

Authors:  Yng-Ching Wu; Tim Jaglinski; Jin-Yuan Hsieh; Jia-Jyun Chiu; Tzen-Yuh Chiang; Chi-Chuan Hwang
Journal:  J Mol Model       Date:  2011-05-27       Impact factor: 1.810

7.  Cyclic Biphalin Analogues Incorporating a Xylene Bridge: Synthesis, Characterization, and Biological Profile.

Authors:  Azzurra Stefanucci; Alfonso Carotenuto; Giorgia Macedonio; Ettore Novellino; Stefano Pieretti; Francesca Marzoli; Edina Szűcs; Anna I Erdei; Ferenc Zádor; Sándor Benyhe; Adriano Mollica
Journal:  ACS Med Chem Lett       Date:  2017-07-12       Impact factor: 4.345

Review 8.  Organic chemistry and biology: chemical biology through the eyes of collaboration.

Authors:  Victor J Hruby
Journal:  J Org Chem       Date:  2009-12-18       Impact factor: 4.354

9.  Modeling and simulation of the human delta opioid receptor.

Authors:  Mahalaxmi Aburi; Paul E Smith
Journal:  Protein Sci       Date:  2004-07-06       Impact factor: 6.725

10.  Bioactive conformations of two seminal delta opioid receptor penta-peptides inferred from free-energy profiles.

Authors:  Guido Scarabelli; Davide Provasi; Ana Negri; Marta Filizola
Journal:  Biopolymers       Date:  2014-01       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.